Clinical Trial Update: A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing crizotinib to pemetrexed-platinum chemotherapy in patients with ALK-positive non-small cell lung cancer has completed. Pfizer-sponsore…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Crizotinib (crizotinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Pfizer | Conditions: Non Squamous Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2015-01-05